Quantessence Capital’s Fulgent Genetics FLGT Stock Holding History

Quantessence Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,100	Closed	-$171K	–	275
2025 Q1	$171K	Buy	+10,100	New	+$172K	0.04%	288

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Quantessence Capital's FLGT Position: Q2 2025 in Review

Quantessence Capital sold out of Fulgent Genetics (FLGT) in Q2 2025, closing a stake of 10,100 shares — an estimated $171K sold.

Quantessence Capital first reported a position in FLGT in Q1 2025 and held it in 1 quarter. The position peaked at $171K in Q1 2025. 167 funds tracked by Wall St. Rank hold FLGT as of Q2 2025.

Quantessence Capital reported no remaining Fulgent Genetics position as of Q2 2025 after selling out during the quarter.
Quantessence Capital sold 10,100 Fulgent Genetics shares in Q2 2025, an estimated $171K.
Quantessence Capital first reported a position in Fulgent Genetics in Q1 2025 and held it in 1 quarter.
Quantessence Capital's Fulgent Genetics position peaked at $171K in Q1 2025.
167 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.